Study of the Impact of a Physical Activity Programme on the Quality of Life of Patients With Inflammatory Bowel Disease (APMICI)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Crohn's disease and haemorrhagic rectocolitis are Chronic Inflammatory Bowel Diseases (CIBD) which evolve by flare-ups interspersed with periods of remission . The incidence of these two diseases is increasing in France in adults but also and especially in children and adolescents. Indeed, according to data from the EPIMAD registry, from 1988-1990 to 2009-2011, a significant increase in the incidence of both Crohn's disease and haemorrhagic rectocolitis was observed in adolescents (10-16 years): for Crohn's disease from 4.2 to 9.5/10 5 (+126%; P <0.001) and for UC from 1.6 to 4.1/10 5 (+156%; P <0.001). Over the long term, Crohn's disease can progress to intestinal destruction that can be complicated by stricture(s), obstruction(s), fistula(s) and/or abscesses leading to surgical treatment estimated at 50% after 10 years of Crohn's disease progression 1.
Anti-TNFα therapies are widely prescribed for Crohn's disease because they control symptoms, heal the mucosa, reduce hospital admissions and improve quality of life. However, they are associated with side effects often reported by patients, such as asthenia, weight gain and joint pain, symptoms that could be improved by regular physical activity.
Regular physical activity at a mild to moderate intensity can control inflammation in general and intestinal inflammation in particular during IBD. The effectiveness of a physical activity programme has been evaluated during IBD, but the data are limited to a few studies. Overall, PA improves quality of life but also improves control of disease symptoms and fatigue . The aim of the present work is to evaluate the impact of a physical activity programme on quality of life in patients with IBD. This programme will also evaluate the impact of physical activity on 1) anxiety-depression, 2) fatigue (a frequent and difficult to manage symptom in IBD), 3) IBD activity, 4) smoking cessation.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Stéphane Nahon, MD
- Phone Number: 0141708121
- Email: gastronahon@gmail.com
Study Locations
-
-
-
Montfermeil, France, 93370
- Recruiting
- Stéphane Nahon
-
Contact:
- Stéphane R Nahon, MD
- Phone Number: 0141708121
- Email: stephane.nahon@ght-gpne.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient followed for IBD in the hospital of Montfermeil
- over 18 years of age
- medical certificate authorising the practice of physical activity
- Informed consent
Exclusion Criteria:
- Age < 18 years
- Medical contraindication to physical activity
- Objection to participation in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: patients with physical activity
A group of patients with physical activity (protocolized)
|
physical activity
|
|
NO_INTERVENTION: patients without physical activity
A group of patients without physical activity (protocolised)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON THE QUALITY OF LIFE OF PATIENTS
Time Frame: 6 months
|
EVALUATE THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON THE QUALITY OF LIFE OF PATIENTS WITH IBD (assessment by IBDQ score)
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the impact of the physical activity programme on Psychological state
Time Frame: 6 months
|
To measure the impact of the physical activity programme on Psychological state (HAD score)
|
6 months
|
|
the impact of the physical activity programme on fatigue (FACIT score)
Time Frame: 6 months
|
the impact of the physical activity programme on fatigue (FACIT score)
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Stéphane Nahon, MD, Raincy Montfermeil Hospital Group
Publications and helpful links
General Publications
- Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017 Apr 29;389(10080):1741-1755. doi: 10.1016/S0140-6736(16)31711-1. Epub 2016 Dec 1.
- Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017 Apr 29;389(10080):1756-1770. doi: 10.1016/S0140-6736(16)32126-2. Epub 2016 Dec 1.
- Gower-Rousseau C, Vasseur F, Fumery M, Savoye G, Salleron J, Dauchet L, Turck D, Cortot A, Peyrin-Biroulet L, Colombel JF. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis. 2013 Feb;45(2):89-94. doi: 10.1016/j.dld.2012.09.005. Epub 2012 Oct 27.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2018-A02807-48
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease Haemorrhagic Rectocolitis
-
NCT06632691Recruiting
-
NCT06555042RecruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn Disease in Remission | Crohn Disease of Small Intestine
-
NCT07231601RecruitingCrohn Disease (CD) | Crohn Disease of Ileum | Kono S Anastomosis | Extended Mesenteric Excision
-
NCT07010926Not yet recruitingCrohn&Amp;#39;s | Crohn&Amp;#39;s Disease (CD)
-
NCT07471438Not yet recruiting
-
NCT07413653Not yet recruiting
-
NCT07316621Not yet recruiting
-
NCT07308067Active, not recruiting
-
NCT07625293Not yet recruitingCrohn Disease (CD)
Clinical Trials on physical activity
-
NCT04221022CompletedPhysical Activity and Stress
-
NCT04941014Completed
-
NCT07630272Completed
-
NCT02044887Completed
-
NCT02753231CompletedObesity | Lipid Metabolism Disorders | Mental Health Wellness 1 | Body Composition, Beneficial | Metabolic Syndrome X
-
NCT06377254RecruitingMetabolic Syndrome | Sedentary Behavior | Age-related Cognitive Decline | Age-Related Sarcopenia
-
NCT05831735RecruitingQuality of Life | Endometriosis
-
NCT05306652RecruitingNon-Small Cell Lung Cancer